- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03512249
Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence
Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Evaluate Safety and Efficacy of H56:IC31 in Reducing the Rate of TB Disease Recurrence in HIV Negative Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis
This is a phase 2, double-blind, randomized (1:1), placebo-controlled trial with two parallel groups.
- H56:IC31 (investigational vaccine)
Placebo
900 HIV-negative adults with a diagnosis of drug susceptible pulmonary TB are planned to be included, recruited from TB clinics with established relationships to the trial sites at the start of their TB treatment.
5 study sites in South Africa: 2 sites from the AURUM institute (Klerksdorp and Tembisa) and 3 in Cape Town at TASK Applied Science (TASK), the University of Cape Town Lung Institute (UCTLI) and South African Tuberculosis Vaccine Initiative (SATVI) under UCT, respectively.
1 study site in Tanzania (TZ): 1 site at Mbeya Medical Research Centre (MMRC) under the National Institute for Medical Research (NIMR).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase 2, double-blind, randomized (1:1), placebo-controlled trial with two parallel groups.
- H56:IC31 (investigational vaccine)
Placebo
900 HIV-negative adults with a diagnosis of drug susceptible pulmonary TB are planned to be included, recruited from TB clinics with established relationships to the trial sites at the start of their TB treatment.
5 study sites in South Africa: 2 sites from the AURUM institute (Klerksdorp and Tembisa) and 3 in Cape Town at TASK Applied Science (TASK), the University of Cape Town Lung Institute (UCTLI)) and South African Tuberculosis Vaccine Initiative (SATVI) under UCT, respectively.
1 study site in Tanzania (TZ): 1 site at Mbeya Medical Research Centre (MMRC) under the National Institute for Medical Research (NIMR).
Preclinical data suggest H56:IC31 may be more efficacious if administered while patients are still on treatment. Following the national guidelines for TB treatment in South Africa and Tanzania, we will obtain sputum samples from patients towards the end of treatment at about the same time they are obtained within the national TB control programmes, and if the sputum is smear negative, the criterion for successful treatment within TB programmes, the individual will be eligible for randomization and vaccination towards the end of their six-month treatment period.
As this is a proof of concept TB vaccine study, HIV positive individuals have been excluded as it is not yet known what effect HIV infection may have on the immune response to the vaccine. However, HIV positive individuals are an important population to include in future studies should efficacy be demonstrated in this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Dereck Tait, MD
- Phone Number: +27 (0)21 344 1200
- Email: dtait@iavi.org
Study Contact Backup
- Name: Mildie Leuvennink
- Phone Number: +27 (0)21 344 1200
- Email: mleuvennink@iavi.org
Study Locations
-
-
Cape Town
-
Bellville, Cape Town, South Africa, 7530
- Task Clinical Research Centre
-
Mowbray, Cape Town, South Africa
- University of Cape Town Lung Institute
-
-
Gauteng
-
Tembisa, Gauteng, South Africa, 1632
- The Aurum Institute: Tembisa Clinical Research Centre
-
-
North-West
-
Klerksdorp, North-West, South Africa, 2570
- The Aurum Institute
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 6850
- South African Tuberculosis Vaccine Initiative , Project Office, Brewelskloof Hospital , Harlem Street, Worcester
-
-
-
-
-
Mbeya, Tanzania
- NIMR Mbeya Medical Research Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Completed the written informed consent process.
- Agrees to give access to medical records for trial related purposes.
- Was HIV-negative (self-reported) with a diagnosis of drug susceptible pulmonary TB at the start of the TB treatment.
- Able to provide 2 separate sputum samples within ≤ 7 days of starting TB treatment. Participants are not expected to provide sputum samples prior to starting TB treatment if their 1st screening visit (V1) is performed on the same day as their 2nd screening visit (V2).
- Confirmed Mtb negative by smear AFB microscopy of 2 separate sputum samples taken at V2. Participants unable to produce sputum, but considered asymptomatic by the investigator, may be considered Mtb negative and eligible for inclusion.
- Confirmed HIV negative at V2.
- Completed ≥ 5 months (22 weeks) of TB treatment with treatment still ongoing at the time of the 1st vaccination and total treatment time not extended beyond 28 weeks.
- Aged ≥ 18 years on the date of V1 and ≤ 60 years on the date of V3= Day 0.
- Agrees to stay in contact with the clinical trial site for the duration of the trial, provide updated contact information as necessary, and has no current plans to move from the area for the duration of the trial.
Exclusion Criteria:
- Diagnosis or co-diagnosis of extra pulmonary TB.
- Hospitalized for the current episode of drug susceptible pulmonary TB disease.
- History of or ongoing severe disease that in the opinion of the investigator might affect the safety of the participant or the immunogenicity of the investigational product.
- Insulin dependent diabetes.
- History of allergic disease or reactions likely to be exacerbated by any component of the investigational product.
- History or laboratory evidence of immunodeficiency, autoimmune disease or immunosuppression.
- History of chronic hepatitis.
- Severe anemia, defined as hemoglobin less than 10 g/dL or a hematocrit less than 30% based on most recent hematology obtained before randomization.
- History of receipt of treatment against active TB, prior to the current treatment episode, within the last 5 years
- Receipt of any investigational TB vaccine previously.
- Receipt or planned receipt of any investigational drug or investigational vaccine from V1 through V8= Day 421.
- Receipt or planned receipt of any licensed vaccine from V1 through V6= Day 70, except for SARS-Cov-2 vaccines recommended by national vaccination programs which will be allowed if given > 28 days before and from the time of administration of clinical trial product.
- Receipt of treatment likely to modify the immune response (e.g. blood products, immunoglobulins, immunosuppressive treatment) within 42 days before V3= Day 0 through V6= Day 70. Inhaled and topical corticosteroids are permitted.
- Has a body mass index (BMI) < 13 (weight, kg / height, m2) on the date of V1.
- Female participants of childbearing potential (not sterilized, menstruating or within 1 year of last menses, if post-menopausal): if not willing to use an acceptable method to avoid pregnancy (sterile sexual partner, sexual abstinence, hormonal contraceptives (oral, injection, transdermal patch, or implant) or intrauterine device from 28 days before V3= Day 0 until 2 months after the 2nd vaccination.
- Female participants: if lactating / nursing, or pregnant as per positive pregnancy test on V2.
- Not suitable for inclusion in the opinion of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: H56:IC31
The H56 fusion protein is formulated with IC31 in a GMP-compliant environment in a ready to use final formulated vaccine. H56:IC31 is administered twice with a 56 days (+/-10) interval, as 5 μg H56 adjuvanted with IC31 consisting of 500 nmol KLK and 20 nmol ODN1a, in a total volume of 0.5mL by the intramuscular route in the deltoid area using standard aseptic technique. |
5ug H56/500 nmol IC31
Other Names:
|
Placebo Comparator: Placebo
Sterile saline for injection
|
Sterile saline for injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
• Rate of TB disease recurrence (relapse or reinfection), defined as TB diagnosed by confirmation of Mtb by culture of sputum.
Time Frame: During the period starting 14 days after the 2nd vaccination (V6= Day 70) and ending 12 months after the 2nd vaccination
|
Efficacy of H56:IC31 compared to placebo in reducing the rate of recurrent TB disease (relapse or reinfection)
|
During the period starting 14 days after the 2nd vaccination (V6= Day 70) and ending 12 months after the 2nd vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Solicited adverse events and all adverse events occurring the first 14 days after each of the 1st and 2nd vaccinations
Time Frame: Day 0 thru Day 70
|
Safety of H56:IC31 compared to placebo
|
Day 0 thru Day 70
|
Serious adverse events including medically important events occurring after the 1st vaccination through the end of the trial
Time Frame: Day 0 thru Day 421
|
Safety of H56:IC31 compared to placebo
|
Day 0 thru Day 421
|
Efficacy of H56:IC31 compared to placebo in reducing the rate of TB disease relapse
Time Frame: Day 0 thru Day 421
|
Rate of TB relapse defined as subjects meeting the primary endpoint of TB disease recurrence, AND determined by whole genome sequencing (WGS) of the Mtb isolate to be the same strain of Mtb as in the subject's original isolate from the time of diagnosis
|
Day 0 thru Day 421
|
Efficacy of H56:IC31 compared to placebo in reducing the rate of TB disease reinfection
Time Frame: Day 0 thru Day 421
|
Rate of TB disease reinfection defined as subjects meeting the primary endpoint of TB disease recurrence, AND determined by WGS of the Mtb isolate to be a different strain than in the subject's original isolate from the time of diagnosis.
|
Day 0 thru Day 421
|
Antigen-specific cell-mediated immune responses to H56:IC31
Time Frame: Day 0 thru Day 70
|
Antigen-specific cell-mediated immune responses by peripheral blood mononuclear cells (PBMC) intracellular cytokine staining (ICS) at baseline (V3= Day 0) and 14 days after the 2nd vaccination (V6= Day 70) and at TB recurrence diagnosis
|
Day 0 thru Day 70
|
Humoral immune responses to H56:IC31
Time Frame: Day 0 thru Day 70
|
Humoral immune responses by IgG ELISA of plasma samples at baseline (V3= Day 0) and 14 days after the 2nd vaccination (V6= Day 70) and at TB recurrence diagnosis
|
Day 0 thru Day 70
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Marissa Russell, IAVI (previously Aeras)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Disease Attributes
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Recurrence
- Tuberculosis
- Tuberculosis, Pulmonary
Other Study ID Numbers
- A-055
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis, Pulmonary
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Tjip van der WerfGadjah Mada University; The Enose Company, Zutphen the NetherlandsCompletedPulmonary Tuberculosis Suspected | Other Specified Chronic Obstructive Pulmonary Disease | Pulmonary Tuberculosis TB (+) Histology, (-) BacteriologyIndonesia
-
Research Institute of Epidemiology, Microbiology...Active, not recruitingAspergillosis | Pulmonary Tuberculoses | Old Tuberculosis | Active Tuberculosis | Chronic Pulmonary AspergillosisUzbekistan
-
Medecins Sans Frontieres, NetherlandsLondon School of Hygiene and Tropical Medicine; University of Liverpool; Ministry... and other collaboratorsRecruitingMulti-drug Resistant Tuberculosis | Pulmonary Tuberculoses | Extensively Drug-Resistant TuberculosisBelarus, South Africa, Uzbekistan
-
Radboud University Medical CenterEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Department... and other collaboratorsCompletedPulmonary Tuberculosis (TB)South Africa
-
National Institute of Allergy and Infectious Diseases...International Tuberculosis Research CenterWithdrawnRefractory Pulmonary TuberculosisKorea, Republic of
-
Assiut UniversityUnknownExtra Pulmonary Tuberculosis
-
Karolinska InstitutetAddis Ababa University; Armauer Hansen Research Institute, EthiopiaCompleted
-
Assistance Publique - Hôpitaux de ParisUnknownPulmonary Tuberculosis | Extra Pulmonary TuberculosisFrance
Clinical Trials on H56:IC31
-
AerasOslo University Hospital; University of Copenhagen; University of Bergen; Aurum... and other collaboratorsWithdrawnTuberculosis InfectionSouth Africa, Tanzania
-
AerasStatens Serum InstitutCompleted
-
AerasStatens Serum InstitutCompletedLatent Tuberculosis | Latent Tuberculosis Bacteriology and Histology UnknownSouth Africa
-
AerasSanofi Pasteur, a Sanofi Company; Statens Serum Institut; HIV Vaccine Trials...CompletedTuberculosisSouth Africa
-
Anne Margarita Dyrhol RiiseUniversity of Oslo; Haukeland University Hospital; Statens Serum InstitutCompleted
-
Altimmune, Inc.CompletedHepatitis BKorea, Republic of, United Kingdom
-
Statens Serum InstitutCompleted
-
Statens Serum InstitutCompleted
-
AerasStatens Serum InstitutCompletedTuberculosisSouth Africa
-
AerasSanofi Pasteur, a Sanofi CompanyCompleted